# Staccato Loxapine in Agitated Patients With Schizophrenia

> **NCT00628589** · PHASE3 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 344 (actual)

## Conditions studied

- Patients With Schizophrenia and Acute Agitation

## Interventions

- **DRUG:** Inhaled loxapine 5 mg
- **DRUG:** Inhaled loxapine 10 mg
- **DRUG:** Inhaled placebo

## Key facts

- **NCT ID:** NCT00628589
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628589, "Staccato Loxapine in Agitated Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00628589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*